MAJA STROLLO: Open Payments
NPI 1154028009 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,831 in 115 payments from 23 companies in 2025. Trend: 2023 $1,203 · 2024 $1,887 · 2025 $2,831
Food & beverage: $2,815Education: $16
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $562 |
| Janssen Biotech, Inc. | 13 | $389 |
| Novo Nordisk Inc | 4 | $206 |
| Gilead Sciences, Inc. | 9 | $200 |
| QOL Medical, LLC | 6 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $170 |
| Aimmune Therapeutics, Inc. | 6 | $152 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $129 |
| Ardelyx, Inc. | 5 | $125 |
| Madrigal Pharmaceuticals | 5 | $116 |
Products named: TREMFYA, RINVOQ, Wegovy, Sucraid, SKYRIZI, XIFAXAN, IBSRELA, REZDIFFRA.
Industry payments across VA — which companies pay providers there.
